Tommy Andersson
Stefan Hudak


  • Academy of Medical Sciences of USSR, Romodanov Institute of Neurosurgery (Kiev), neurosurgery training under the lidership of pioneers of endovascular neurosurgery Victor Scheglov and Fedor Serbinenko, 1988-1998
  • Romodanov Institute of Neurosurgery (Kiev), Center of Endovascular Neurosurgery, clinical chief, 1996-1998
  • PHD: Endovascular Method in Treatment of Vertebro-Basilar Aneurysms, Academy of Medical Sciences of the Ukraine, Romodanov Institute of Neurosurgery, 1998
  • Medical University of Pecs (Hungary), Department of Neurosurgery, visiting professor, 1998-2000
  • First Combined transarterial-transvenous approach in AVM treatment with new polyurethane-based liquid polymer (Hudak Embolizing Liquid Polymer - HELP), 1999
  • University of Pecs (Hungary), Clinical Center, Department of Neurosurgery, chief of endovascular neurointervention unit, 2000-2017
  • Neurochirurgische Universitaetsklinik, Nijmegen (Netherlands), visiting professor, Combined transarterial-transvenous AVM embolization 2015
  • San Carlos Hospital Clinico, Madrid (Spain), Combined transarterial-transvenous AVM embolization, 2016
  • Hungarian Defence Forces Military Hospital Budapest (Hungary), Department of Neurosurgery, chief of endovascular unit, 2017-


  • Bogomolets National Medical University, Kiev, 1988
  • Course of Neurosurgery, National Medical Academy of Postgraduate education, Kiev, 1989
  • Specialist of Neurosurgery, Academy of Medical Sciences of Ukrain, Romodanov Institute of Neurosurgery, Kiev, 1994
  • Angiography and endovascular surgery, National Medical Academy of Postgraduate education, Kiev, 1994


  • New understanding of the nature of malformations - Combined transarterial-transvenous embolisation of AVMs.
  • Treatment of all grade brain AVMs.
  • Pediatric neurointervention, vein of Galen aneurysmal malformation.
  • Multiplex aneurysms management.
  • Fenestration as the source of bleeding.
  • Dural fistula management.
  • AVM of spinal cord.
  • Carotideo-cavernous fistula.
  • Stroke, thrombectomy.
  • Embolisation of highly vascularized tumors.
  • Endovascular treatment of hemangiomas, Osler disease, otolar√≠ngologic tumors.
  • Development of new polyutethane-based liquie embolic agent with disappearing contrast material for the endovascular treatment of saccular aneurysms, AVMs and highly vascularized tumors.